|
|
||||||||||||||
|
|
|||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
1 ELEGI/Colt Laboratory, Centre for Inflammation Research, University of Edinburgh, Medical School, Edinburgh EH8 9AG, UK
2 Royal Infirmary Edinburgh, Little France, Edinburgh EH16 4SA, UK
3 Servei de Pneumologia and Unitat dinvestigacio, Hospital Universitari son Dureta, Palma de Mallorca, Spain
4 Servei de Pneumologia (ICPCT), Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
Correspondence to:
Correspondence to:
Dr E M Drost
ELEGI Laboratory, MRC Centre for Inflammation Research, University of Edinburgh, Medical School, Teviot Place, Edinburgh EH8 9AG, UK; Ellen.Drost{at}ed.ac.uk
Background: A study was undertaken to assess both oxidative stress and inflammation in the lungs of patients with chronic obstructive pulmonary disease (COPD) during severe and very severe exacerbations compared with those with stable COPD, healthy smokers, and non-smokers. Two sites within the lungs were compared: the large airways (in sputum) and the peripheral airways (by bronchoalveolar lavage (BAL)).
Methods: BAL fluid cell numbers and levels of tumour necrosis factor (TNF
) and interleukin (IL)-8 were measured as markers of airway inflammation and glutathione (GSH) levels as a marker of antioxidant status. Nuclear translocation of the pro-inflammatory transcription factors nuclear factor-
B (NF-
B) and activator protein 1 (AP-1) were also measured by electromobility shift assay in BAL fluid leucocytes and lung biopsy samples.
Results: Influx of inflammatory cells into the peripheral airways during exacerbations of COPD was confirmed. Increased IL-8 levels were detected in BAL fluid from patients with stable COPD compared with non-smokers and healthy smokers, with no further increase during exacerbations. In contrast, IL-8 levels in the large airways increased during exacerbations. GSH levels were increased in the BAL fluid of smokers (444%) and patients with stable COPD (235%) compared with non-smokers and were reduced during exacerbations (severe 89.2%; very severe 52.3% compared with stable COPD). NF-
B DNA binding in BAL leucocytes was decreased in healthy smokers compared with non-smokers (41.3%, n = 9, p<0.001) but did not differ in COPD patients, whereas AP-1 DNA binding was significantly decreased during exacerbations of COPD.
Conclusion: There is evidence of increased oxidative stress in the airways of patients with COPD that is increased further in severe and very severe exacerbations of the disease. This is associated with increased neutrophil influx and IL-8 levels during exacerbations.
Abbreviations: AP-1, activator protein 1; COPD, chronic obstructive pulmonary disease; EMSA, electrophoretic mobility shift assay,
-GCS, gamma-glutamylcysteine synthetase; GSH, glutathione; IL, interleukin; NF-
B, nuclear factor-
B; TNF
, tumour necrosis factor 
Keywords: chronic obstructive pulmonary disease; nuclear factor-
B; interleukin 8; oxidative stress; glutathione; inflammation
Relevant Article
Thorax 2005 60: 263.
This article has been cited by other articles:
![]() |
I. Rahman Review: Antioxidant therapeutic advances in COPD Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 351 - 374. [Abstract] [PDF] |
||||
![]() |
R. Do, K. H. Bartlett, H. Dimich-Ward, W. Chu, and S. M. Kennedy Biomarkers of Airway Acidity and Oxidative Stress in Exhaled Breath Condensate from Grain Workers Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1048 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Malhotra, R. Thimmulappa, A. Navas-Acien, A. Sandford, M. Elliott, A. Singh, L. Chen, X. Zhuang, J. Hogg, P. Pare, et al. Decline in NRF2-regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator, DJ-1 Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 592 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Petrache, T. R. Medler, A. T. Richter, K. Kamocki, U. Chukwueke, L. Zhen, Y. Gu, J. Adamowicz, K. S. Schweitzer, W. C. Hubbard, et al. Superoxide dismutase protects against apoptosis and alveolar enlargement induced by ceramide Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L44 - L53. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Kelsen, X. Duan, R. Ji, O. Perez, C. Liu, and S. Merali Cigarette Smoke Induces an Unfolded Protein Response in the Human Lung: A Proteomic Approach Am. J. Respir. Cell Mol. Biol., May 1, 2008; 38(5): 541 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Abusriwil and R. A. Stockley The Interaction of Host and Pathogen Factors in Chronic Obstructive Pulmonary Disease Exacerbations and Their Role in Tissue Damage Proceedings of the ATS, December 1, 2007; 4(8): 611 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Martinez Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Singh Inhaled steroids in exacerbations of COPD Eur. Respir. J., August 1, 2007; 30(2): 398 - 398. [Full Text] [PDF] |
||||
![]() |
T. Yoshida and R. M. Tuder Pathobiology of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Physiol Rev, July 1, 2007; 87(3): 1047 - 1082. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Perera, J. R. Hurst, T. M. A. Wilkinson, R. J. Sapsford, H. Mullerova, G. C. Donaldson, and J. A. Wedzicha Inflammatory changes, recovery and recurrence at COPD exacerbation Eur. Respir. J., March 1, 2007; 29(3): 527 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Ritz, J. Wan, and D. Diaz-Sanchez Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L33 - L39. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Singh, T. Rangasamy, R. K. Thimmulappa, H. Lee, W. O. Osburn, R. Brigelius-Flohe, T. W. Kensler, M. Yamamoto, and S. Biswal Glutathione Peroxidase 2, the Major Cigarette Smoke-Inducible Isoform of GPX in Lungs, Is Regulated by Nrf2 Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 639 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mallia and S. L. Johnston How viral infections cause exacerbation of airway diseases. Chest, October 1, 2006; 130(4): 1203 - 1210. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Agusti Thomas A. Neff Lecture. Chronic Obstructive Pulmonary Disease: A Systemic Disease Proceedings of the ATS, August 1, 2006; 3(6): 478 - 481. [Full Text] [PDF] |
||||
![]() |
A. M. Knaapen, N. Gungor, R. P. F. Schins, P. J. A. Borm, and F. J. Van Schooten Neutrophils and respiratory tract DNA damage and mutagenesis: a review Mutagenesis, July 1, 2006; 21(4): 225 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Rodriguez-Roisin COPD exacerbations {middle dot} 5: Management. Thorax, June 1, 2006; 61(6): 535 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
M A Dentener, R Louis, R H E Cloots, M Henket, and E F M Wouters Differences in local versus systemic TNF{alpha} production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNF{alpha} release Thorax, June 1, 2006; 61(6): 478 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Birrell, S. Wong, E. L. Hardaker, M. C. Catley, K. McCluskie, M. Collins, S. Haj-Yahia, and M. G. Belvisi I{kappa}B Kinase-2-Independent and -Dependent Inflammation in Airway Disease Models: Relevance of IKK-2 Inhibition to the Clinic Mol. Pharmacol., June 1, 2006; 69(6): 1791 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Nagai, T Betsuyaku, T Kondo, Y Nasuhara, and M Nishimura Long term smoking with age builds up excessive oxidative stress in bronchoalveolar lavage fluid Thorax, June 1, 2006; 61(6): 496 - 502. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF] |
||||
![]() |
J. A. Wedzicha and T. Wilkinson Impact of Chronic Obstructive Pulmonary Disease Exacerbations on Patients and Payers Proceedings of the ATS, May 1, 2006; 3(3): 218 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Papi, F. Luppi, F. Franco, and L. M. Fabbri Pathophysiology of Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2006; 3(3): 245 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. F. M. Wouters Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several? Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
R O'Donnell, D Breen, S Wilson, and R Djukanovic Inflammatory cells in the airways in COPD Thorax, May 1, 2006; 61(5): 448 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Hurst, W. R. Perera, T. M. A. Wilkinson, G. C. Donaldson, and J. A. Wedzicha Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 71 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Owen Proteinases and Oxidants as Targets in the Treatment of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 373 - 385. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |